Chris Tan is a partner at Outram Bio, a healthcare and life sciences venture capital firm headquartered in Singapore. He brings over twenty years of investment experience in the U.S.—before co-founding Outram Bio, he was a partner at Ebbtide Investors, a San Francisco-based private investment firm, and FTV Capital, a $6 billion growth equity firm, where he focused on healthcare and enterprise technology. Prior to that, he worked at HeyAnita, a voice recognition technology company backed by SOFTBANK and Intel Capital, and subsequently acquired by Kirusa. Chris started his career as an analyst at Goldman Sachs Capital Partners in New York. Chris graduated summa cum laude from the University of Pennsylvania’s Management & Technology program, with dual degrees in BSEcon (Finance) from The Wharton School and BAS (Computer Science) from the School of Engineering and Applied Science.